[1] Krieger C A, Cunningham J L, Grothe K B, et al.Comparisonof Bioavailability of Single-Dose Extended-Release VenlafaxineCapsules in Obese Patients Before and After Gastric BypassSurgery[J]. Pharmacotherapy, 2017, 37(11): 1374-1382. [2] 颜彪华,李兵. 结核合并肝损伤对抗结核药物血药浓度的影响[J]. 当代医学, 2013, 19(10): 30-31. [3] 肖和平. 抗结核药物的合理使用是控制耐药结核病流行的基石[J]. 中华结核和呼吸杂志, 2014, 37(10): 723-724. [4] Lv X Z, Tang S W, Xia Y Y, et al.Adverse reactions due todirectly observed treatment strategy therapy in Chinesetuberculosis patients: a prospective study[J]. PLoS One,2013, 8(6): e65037. [5] Weiner M, Burman W, Vernon A, et al.Low isoniazid concentrationsand outcome of tuberculosis treatment with once-weeklyisoniazid and rifapentine[J]. Am J Resp Crit Care, 2003,167(10): 1341-1347. [6] Dheda K, Gumbo T, Gandhi N R, et al.Global control oftuberculosis: from extensively drug-resistant to untreatabletuberculosis[J]. Lancet Respir Med, 2014, 2(4): 321-338. [7] Jing Y, Zhu L Q, Yang J W, et al.Population pharmacokineticsof rifampicin in Chinese patients with pulmonary tuberculosis[J]. J Clin Pharmacol, 2016, 56(5): 622-627. [8] 赵冠仁,彭明丽,申健,等. HPLC-MS/MS方法同时检测人血浆中异烟肼、利福平、乙胺丁醇、吡嗪酰胺和左氧氟沙星的浓度[J]. 中国药物应用与监测, 2015, 12(1):16-19. [9] 魏香兰,方如塘,师延峰,等. 抗结核药物的血药浓度监测结果分析[J]. 中国医院药学杂志, 2015, 35(21): 1918-1921. [10] 赵嫄,雷倩,党丽云,等. 抗结核药物血药浓度监测工作的思考和展望[J]. 中国防痨杂志, 2017, 39(11): 1228-1232. [11] World Health Organization.Global Tuberculosis Control:WHO Report 2016[R]. Geneva: World Health Organization,2016. [12] Choi R, Jeong B H, Koh W J, et al.Recommendations forOptimizing Tuberculosis Treatment: Therapeutic Drug Monitoring,Pharmacogenetics, and Nutritional Status Considerations[J].Ann Lab Med, 2017, 37(2): 97-107. [13] Alsultan A, Peloquin C A.Therapeutic drug monitoring in thetreatment of tuberculosis: an update[J]. Drugs, 2014, 74(8):839-854. [14] 汪复, 张婴元. 实用抗感染治疗学[M]. 2版. 北京:人民卫生出版社, 2013:104-109. [15] Devaleenal D B, Ramachandran G, Swaminathan S.Thechallenges of pharmacokinetic variability of first-line anti-TB drugs[J]. Expert Rev Clin Pharmacol, 2017, 10(1): 47-58. [16] 周俊,吕小会,刘元,等. 三种抗结核药物血药浓度在个体及药物间的差异研究[J]. 中国防痨杂志, 2017, 39(5):482-487. [17] Srinivas N R.Pharmacokinetic Interaction of Rifampicinwith Oral Versus Intravenous Anticancer Drugs: Challenges,Dilemmas and Paradoxical Effects Due to Multiple Mechanisms[J]. Drugs R D, 2016, 16(2): 141-148. [18] Jiao Y, Kim T H, Tao X, et al.First population pharmacokineticanalysis showing increased quinolone metabolite formationand clearance in patients with cystic fibrosis compared tohealthy volunteers[J]. Eur J Pharm Sci, 2018, 123(1): 416-428. [19] Wang P C, Pradhan K, Zhong X B, et al.Isoniazid metabolismand hepatotoxicity[J]. Acta Pharm Sin B, 2016, 6(5): 384-392. [20] 吴雪琼,张宗德,乐军. 分枝杆菌分子生物学[M]. 1版.北京:人民军医出版社, 2010:124-125. [21] Mota L, Al-Efraij K, Campbell J R, et al.Therapeutic drugmonitoring in anti-tuberculosis treatment: a systematic reviewand meta-analysis[J]. Int J Tuberc Lung Dis, 2016, 20(6): 819-826. |